Transforming lives with a clinically validated AI solution for detecting cognitive and mental health using speech.

Late diagnosis of functional cognitive and mental health irregularities can have significant negative impact on treatment. The root of late diagnosis is a delay and difficulty in identifying symptoms. Through its innovative solution, LANGaware makes the detection and monitoring of digital biomarkers based on language and speech a reality, speeding up the process of diagnosis for neurological and cognitive diseases, imporving patient lives and treatment outcomes - tackling late diagnosis at the root. LANGaware was founded in 2019 as a spinout from Demokritos and London's St. George University Hospital by Vassiliki Rentoumi, the company’s CEO. The company uniquely combines its vision to revolutionize disease detection using the power of speech for accessible and efficient cognitive health screening, with Vassiliki’s long-time experience and expertise in academia. Utilizing the latest AI technology and proprietary speech biomarkers, LANGaware can detect subtle changes, providing real-time results while supporting enhanced patient care and treatment, across the healthcare space, including for primary care physicians, pharmaceutical companies and patients. Today, LANGaware works with notable healthcare companies across the US.

The company's founder and CEO, Vassiliki Rentoumi has taken her long-time experience and expertise in academia on Artificial Intelligence, Machine Learning, and Natural Language Processing, and turned it into an intuitive platform to help in the early diagnosis of cognitive and mental health irregularities, helping transform patient lives. The company has received the backing of notable regional investors too.